Introduction: In recent days, the relationship between gender, tumour stage and survival of bladder cancer has attracted interest. Materials and Methods: The Austrian cancer registry was linked to the national death statistics. All patients with urothelial cancer of the urinary bladder with stages pT1, pT2, pT3 and pT4 diagnosed between 1983 until 2012 were followed for up to 15 years. Overall and cancer-specific mortality were estimated by cumulative incidence. Results: A total of 27,773 patients were analysed. The male:female ratio declined from 3:1 for stage pT1-tumours (n = 16,416) to 2.6:1 for pT2 (n = 6,548), 2.1:1 for pT3 (n = 3,111) and 1.9:1 for pT4 (n = 1,698). The 5 years cumulative overall death rate for pT1 tumours was slightly lower for women (0.31 vs. 0.32; p = 0.016). The opposite was observed for more advanced tumour stages: pT2: women 0.66, men: 0.60 (p = 0.0001); pT3: women 0.76, men 0.72 (p = 0.0004) and for pT4: women 0.90, men 0.85 (p = 0.0001). Cancer-specific survival was identical for pT1-tumours in both sexes, while women had a worse cancer-specific survival in both age cohorts (<70 years and ≥70 years) with higher tumour stages. Conclusions: This population-based study demonstrates that (1) a rise of advanced bladder cancer stages in women and (2) that women with tumour stages >pT1 have a shorter cancer-specific and overall survival.

Journal Section:
Editor's choice
Keywords:
Bladder cancer, Gender, Population based, Survival, Tumour stage
1.
Scosyrev E, Trivedi D, Messing E: Female bladder cancer: incidence, treatment, and outcome. Curr Opin Urol 2010;20:404-408.
[PubMed]
https://doi.org/10.1097/MOU.0b013e32833c7a9b
2.
Scosyrev E, Noyes K, Feng C, Messing E: Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer 2009;115:68-74.
[PubMed]
https://doi.org/10.1002/cncr.23986
3.
Mungan NA, Kiemeney LA, van Dijck JA, van der Poel HG, Witjes JA: Gender differences in stage distribution of bladder cancer. Urology 2000;55:368-371.
[PubMed]
https://doi.org/10.1016/S0090-4295(99)00481-1
4.
Mungan NA, Aben KK, Schoenberg MP, et al: Gender differences in stage-adjusted bladder cancer survival. Urology 2000;55:876-880.
[PubMed]
https://doi.org/10.1016/S0090-4295(00)00523-9
5.
Tilki D, Svatek RS, Karakiewicz PI, et al: Characteristics and outcomes of patients with pT4 urothelial carcinoma at radical cystectomy: a retrospective international study of 583 patients. J Urol 2010;183:87-93.
[PubMed]
https://doi.org/10.1016/j.juro.2009.08.145
6.
Svatek RS, Shariat SF, Dinney C, et al: Evidence-based gender related outcomes after radical cystectomy: results of a large multicenter study (abstract #1744). J Urol 2009;181:629.
https://doi.org/10.1016/S0022-5347(09)61766-3
7.
Fajkovic H, Halpern JA, Cha EK, et al: Impact of gender on bladder cancer incidence, staging, and prognosis. World J Urol 2011;29:457-463.
[PubMed]
https://doi.org/10.1007/s00345-011-0709-9
8.
Gray R: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Statist 1988;16:1141-1154.
9.
Shariat SF, Sfakianos JP, Droller MJ, et al: The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int 2010;105:300-308.
[PubMed]
https://doi.org/10.1111/j.1464-410X.2009.09076.x
10.
Gakis G, Stenzl A: Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity. World J Urol 2013;31:1059-1064.
[PubMed]
https://doi.org/10.1007/s00345-013-1037-z
11.
Henning A, Wehrberger M, Madersbacher S, et al: Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer? BJU Int 2013;112:68-73.
[PubMed]
https://doi.org/10.1111/j.1464-410X.2012.11661.x
12.
Aziz A, Madersbacher S, Otto W, et al: Comparative analysis of gender-related differences in symptoms and referral patterns prior to initial diagnosis of urothelial carcinoma of the bladder: a prospective cohort study. Urol Int 2014, Epub ahead of print.
[PubMed]
https://doi.org/10.1159/000363334
13.
Kluth LA, Fajkovic H, Xylinas E, et al: Female gender is associated with higher risk of disease recurrence in patients with primary T1 high-grade urothelial carcinoma of the bladder. World J Urol 2013;31:1029-1036.
[PubMed]
https://doi.org/10.1007/s00345-012-0996-9
14.
Süer E, Özcan C, Baltacı S, et al: Time between first and second transurethral resection of bladder tumors in patients with high-grade T1 tumors: is it a risk factor for residual tumor detection. Urol Int 2013;91:182-186.
[PubMed]
https://doi.org/10.1159/000350512
15.
Otto W, May M, Fritsche HM, et al: Analysis of sex differences in cancer-specific survival and perioperative mortality following radical cystectomy: results of a large German multicentre study of nearly 2500 patients with urothelial carcinoma of the bladder. Gend Med 2012;9:481-489.
[PubMed]
https://doi.org/10.1016/j.genm.2012.11.001
16.
Mitra AP, Skinner EC, Schuckman AK, et al: Effect of gender on outcomes following radical cystectomy for urothelial carcinoma of the bladder: a critical analysis of 1,994 patients. Urol Oncol 2014;52:e1-e9.
[PubMed]
https://doi.org/10.1016/j.urolonc.2013.08.007
17.
Keck B, Ott OJ, Häberle L, et al: Female sex is an independent risk factor for reduced overall survival in bladder cancer patients treated by transurethral resection and radio- or radiochemotherapy. World J Urol 2013;31:1023-1028.
[PubMed]
https://doi.org/10.1007/s00345-012-0971-5
18.
Breyer J, Denzinger S, Otto W, et al: Outcome of patients with pathological tumor stage T3 urothelial carcinoma of the bladder following radical cystectomy in a single-center series with 116 patients. Urol Int 2014;93:311-319.
[PubMed]
https://doi.org/10.1159/000360483
19.
Horstmann M, Witthuhn R, Falk M, et al: Gender-specific differences in bladder cancer: a retrospective analysis. Gend Med 2008;5:385-94.
[PubMed]
https://doi.org/10.1016/j.genm.2008.11.002
© 2015 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2015
You do not currently have access to this content.